Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-281: capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer
MOH_2020-10-20_009426Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) and prostate adenocarcinoma comparing Capivasertib arm with Placebo arm (2 arms). Primary endpoint: Primary endpoint not specified in registry entry. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
capivasertib
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on MOH_2020-10-20_009426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-20_009426.